NLS Pharmaceutics ( (NLSP) ) just unveiled an announcement.
On February 25, 2025, NLS Pharmaceutics, in collaboration with Kadimastem and iTolerance, announced the successful completion of a pre-IND meeting with the FDA for their Type 1 Diabetes treatment, iTOL-102. This milestone marks significant progress in the clinical development of iTOL-102, a potential cure for diabetes that eliminates the need for chronic immune suppression. The collaboration aims to advance the treatment’s development, with support from the Israel-U.S. Binational Industrial Research and Development Foundation. The meeting’s outcome is seen as a validation of the innovative approach and a step towards regulatory approval, potentially transforming diabetes treatment.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a company involved in the pharmaceutical industry, focusing on developing innovative treatments. Kadimastem Ltd., a clinical-stage company, specializes in ‘off-the-shelf’ allogeneic cell therapy products for neurodegenerative diseases and diabetes. iTolerance Inc. is a U.S.-based regenerative medicine company working on technologies to enable cell therapy without the need for life-long immunosuppression.
YTD Price Performance: -12.84%
Average Trading Volume: 2,968,131
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.7M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.